Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioretecOHEL:BRETEC -2.78% Days Payable is 205.21 as of Dec. 2025, which is 99% above its 10-year median of 103.29. The stock has 5 warning signs investors should review. Among 794 Medical Devices & Instruments companies, Bioretec ranks better than 61.84% on this metric.
Bioretec's average Accounts Payable for the
six
months ended in Dec. 2025 was €0.50 Mil. Bioretec's Cost of Goods Sold for the
six
months ended in Dec. 2025 was €0.44 Mil.
Hence, Bioretec's Days Payable for the
six
months ended in Dec. 2025 was 205.21.
The historical rank and industry rank for Bioretec's Days Payable or its related term are showing as below:
OHEL:BRETEC'
s Days Payable Range Over the Past 10 Years
Min: 70.33 Med: 103.29 Max: 179.75
Current: 92.6
During the past 8 years, Bioretec's highest Days Payable was 179.75. The lowest was 70.33. And the median was 103.29.
OHEL:BRETEC's Days Payable is ranked better than 61.84% of 794
companies
in the Medical Devices & Instruments industry
Industry Median: 67.97
vs OHEL:BRETEC: 92.60
Bioretec's Days Payable
increased
from Dec. 2024 (66.04) to Dec. 2025 (205.21).
It may suggest that Bioretecdelayed paying its suppliers.
Bioretec Days Payable Related Terms
Bioretec Days Payable Historical Data
* Premium members only.
The historical data trend for Bioretec's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OHEL:BRETEC vs ABT, SYK, MDT: Days Payable Comparison
For the Medical Devices subindustry, Bioretec's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioretec Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bioretec's Days Payable distribution charts can be found below:
* The bar in red indicates where Bioretec's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Bioretec's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioretec (OHEL:BRETEC) has a Days Payable of 205.21 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bioretec and its competitors. This is 99% above median its historical median of 103.29. Over the past decade, Bioretec's Days Payable has ranged from 70.33 to 179.75. According to the industry distribution chart, Bioretec ranks #303 out of 794 companies in the Medical Devices & Instruments industry, placing it in the top 38.2%.
Is Bioretec's Days Payable too high?
Bioretec's current Days Payable of 205.21 is 99% above median its 10-year median of 103.29. Over the past 10 years, this metric has ranged from a low of 70.33 to a high of 179.75. The Medical Devices & Instruments industry median Days Payable is 67.97. Bioretec's value of 205.21 is 201.9% above this industry median. Based on the distribution chart, Bioretec ranks #303 out of 794 companies in the Medical Devices & Instruments industry, which is above the industry midpoint.
How does Bioretec's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bioretec ranks #303 out of 794 companies for Days Payable. This puts Bioretec in the upper half of its industry. The industry median Days Payable is 67.97. Bioretec's value of 205.21 is 201.9% above this benchmark. Historically, Bioretec's own Days Payable has ranged from 70.33 to 179.75 over the past decade. While the company's 10-year median is 103.29 vs. the industry median of 67.97, Bioretec has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.97, based on 794 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioretec's current Days Payable of 205.21 is 201.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bioretec and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioretec's current Days Payable is 205.21, which is 99% above median its own 10-year median of 103.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioretec stock overvalued right now?
Based on GuruFocus' analysis, Bioretec (OHEL:BRETEC) is currently considered Possible Value Trap. The stock's GF Value™ is €0.19, compared to a current price of €0.02 — trading 88.9% below its estimated fair value. The current Days Payable is 205.21, which is 99% above median its 10-year median of 103.29 and 201.9% above the Medical Devices & Instruments industry median of 67.97. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Bioretec (OHEL:BRETEC), the current Days Payable is 205.21 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bioretec Ltd is a medical device company focusing on the development of bioabsorbable and bioresorbable implants for pediatric and adult orthopedics. It has developed the following product lines: RemeOs and Activa. RemeOs is based on a high-performance magnesium alloy and hybrid composite, introducing absorbable materials for enhanced surgical outcomes. The RemeOs implants (RemeOs Screw Lag, RemeOs Screw Lag Solid, RemeOs Screw FT, etc.) are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The Activa implants (ActivaPin, ActivaNail, ActivaScrew, etc.) are based on fully absorbable biopolymer products that facilitate natural bone healing without requiring removal surgery.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OHEL:BRETEC has been successfully added to your 
